

May 09, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Outcome of the Board Meeting held on Friday, May 09, 2025

Dear Sir/Madam,

In furtherance to our intimation dated May 05, 2025, this is to inform you that pursuant to Regulations 30, 33, and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), the Board of Directors of the Company at its Meeting held today, i.e., May 09, 2025, has inter-alia:-

1. Considered and approved the Unaudited Financial Results for the quarter ended March 31, 2025 and Audited Financial Results of the Company for the financial year ('FY') ended March 31, 2025 (Standalone and Consolidated), along with the Auditor's Report thereon.

A copy of the said results along with the Auditor's Report issued by the Statutory Auditors of the Company is enclosed herewith as **Annexure – I**.

A declaration on auditor's report with unmodified opinion pursuant to the regulation 33(3)(d) of the SEBI Listing Regulations read with SEBI master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ('**SEBI Master Circular**') is enclosed as **Annexure – II**;

2. Recommendation of a dividend @ 10 % i.e. ₹ 1/- per equity share of face value of Rs.10/- each for the FY 2024-25, subject to approval of members at the ensuing Annual General Meeting. The dividend, if approved by the members in the ensuing Annual General Meeting will be paid on or before 30 days from the date of Annual General Meeting. The Book Closure and Record Date for dividend purpose will be intimated in due course;
3. Based on the recommendation of Nomination & Remuneration Committee and Board of Directors has approved appointment of Dr. Ankit Thakker as a Joint Managing Director and Chief Executive Officer of the Company, for a period of five years with effect from July 11, 2025 till July 10, 2030, subject to approval of the members of the Company at the ensuing annual general meeting;

Brief Profile of Dr. Ankit Thakker, in terms of the SEBI Listing Regulations and SEBI Master Circular is annexed herewith as **Annexure – III**;

4. Approved the Scheme of Amalgamation of wholly-owned subsidiary of the Company, viz., Medulla Healthcare Private Limited [hereinafter collectively referred to as the "Transferor Company" with Jupiter Life Line Hospitals Limited (hereinafter referred to as the "Transferee Company" or the

“Company” or “JLHL”) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with relevant rules & regulations framed thereunder.

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure IV**.

5. Considered and approved appointment of Mr. Sivasis Sen as the Chief Financial Officer of the Company with effect from May 12, 2025.

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure V**.

6. Considered and approved continuation of Mr. Harshad Purani as President Administration and Head CSR (Senior Management Personnel) with effect from May 12, 2025.

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure VI**.

7. Considered and approved the appointment of M/s. KKC & Associates LLP, Chartered Accountants as the Statutory Auditor of the Company for the term of five years from the conclusion of the 23rd Annual General Meeting (‘AGM’) till the conclusion of the 28th AGM, subject to the approval by the members of the Company at the ensuing AGM.

Brief Profile of M/s. KKC & Associates LLP, in terms of the SEBI Listing Regulations and SEBI Master Circular is annexed herewith as **Annexure – VII**;

8. Appointment of M/s. Yogesh Sharma & Co, Company Secretaries in Practice, as Secretarial Auditors of the Company, for a period of five consecutive years, commencing from FY 2025-2026 to FY 2029-2030, subject to approval of the members of the Company at the ensuing annual general meeting;

Brief Profile of M/s. Yogesh Sharma & Co., in terms of the SEBI Listing Regulations and SEBI Master Circular is annexed herewith as **Annexure – VIII**;

9. Considered and approved the appointment of M/s. V. J. Talati & Co., Cost Accountant as Cost Auditor of the Company for conducting Cost Audit for FY 2025-2026.

Brief Profile of M/s. V. J. Talati & Co., in terms of the SEBI Listing Regulations and SEBI Master Circular is annexed herewith as **Annexure – IX**;

10. Considered and approved the reappointment of M/s. Varma & Varma, Chartered Accountants as Internal Auditors of the Company for conducting Internal Audit for FY 2025-2026.

Brief Profile of M/s. Varma & Varma, in terms of the SEBI Listing Regulations and SEBI Master Circular is annexed herewith as **Annexure – X**;

11. Approved the change in designation of Dr. Shilpa Tataka from Chief Operating Officer to Chief Executive Officer, Thane, Senior Management Personnel (SMP) of the Company with effect from May 09, 2025.

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure XI**.

12. Approved the change in designation of Mr. Pradip Acharya from Head – Corporate Relations to Group Head – Industrial Health of the Company with effect from May 09, 2025. In view of the aforementioned, he ceases to act as a Senior Management Personnel of the Company.

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure XII**.

13. Approved addition to other object clause of the Memorandum of Association, subject to approval of the members of the Company at the ensuing annual general meeting;

The details as required in terms of SEBI Listing Regulations and SEBI Master Circular are enclosed herewith as **Annexure XIII**.

14. Considered and approved the Notice of 23rd Annual General Meeting (“AGM”) which will be circulated in the due course.

The Board Meeting commenced at 03:00 P.M. and concluded at 4.30 P.M.

This information is also available on the Company’s Website at www.jupiterhospital.com.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking You,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

Aswin P. Malde
F.C.A.

ASWIN P. MALDE & CO.

CHARTERED ACCOUNTANTS

405, Jay Commercial Plaza, Junction of S.L. Road & M.G. Road,
Mulund (W), Mumbai - 400 080. ☎ 6552 5689 Telefax : 2592 5227

Email : aswinmalde@yahoo.co.in • (M) 98202 16031

Independent Auditor's Report on audit of annual consolidated financial results and review of quarterly financial results

TO THE BOARD OF DIRECTORS OF

JUPITER LIFE LINE HOSPITALS LIMITED

Opinion & Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2025 ("the Statement") of JUPITER LIFE LINE HOSPITALS LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/financial information of subsidiaries, the Statement:

i. includes the results of the following entities:

Name of the entity	Relationship
Jupiter Life Line Hospitals Limited	Parent
Jupiter Hospital Projects Private Limited	Subsidiary
Medulla Healthcare Private Limited	Subsidiary
Jupiter Hospital Pharmacy Private Limited	Subsidiary

ii. is presented in accordance with the requirements of Regulation 33 of the LODR Regulations, as amended; and

iii. gives a true and fair view, in conformity with the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income comprising of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2025

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of

Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Parent Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of the full financial year

ended March 31, 2025 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our report on the Statement is not modified in respect of this matter.

- We did not audit/review the financial statements/financial information/financial results of one subsidiary: Jupiter Hospital Projects Private Limited included in the statement whose financial statements/financial information/financial results reflect total assets of Rs. 3244.68 million as at March 31, 2025, total revenue of Rs. 529.03 million and Rs. 2020.91 million for the quarter and the year ended March 31, 2025 respectively, total net profit after tax of Rs.4.25 million and Rs. 88.01 million for the quarter and the year ended March 31, 2025 respectively, total comprehensive income of Rs.1.09 million & Rs.84.85 million for the quarter and the year ended March 31, 2025 respectively and net cash outflow of Rs. (31.53) million for the year ended March 31, 2025, as considered in the Statement.

The independent auditors' reports on financial statements/financial results/financial information of this entity have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.


We did not audit/review the financial statements/financial information/financial results of one subsidiary: Jupiter Hospital Pharmacy Private Limited included in the statement whose financial statements/financial information/financial results reflect total assets of Rs. 0.1 million as at March 31, 2025

Jupiter Hospital Pharmacy Private Limited was converted from a partnership firm to a company during March 2025. The financial statements of said company for the year ended March 31, 2025, have not been audited, as the management has opted to prepare and present the first set of financial statements of the said company for the financial year ending March 31, 2026, in accordance with the applicable provisions. Our opinion on the consolidated financial statements is not modified in respect of this matter.

For ASWIN P. MALDE & CO.

Chartered Accountants

Firm's Registration No. 100725W



ASWIN P. MALDE

(Proprietor)

Membership No. 032662

UDIN 25032662BMJBTT2682

Place: Mumbai

Date: May 9, 2025




Jupiter Life Line Hospitals Limited
Audited Consolidated Balance Sheet as at March 31, 2025

Particulars	₹ In Million	
	As at March 31, 2025	As at March 31, 2024
ASSETS		
Non-current assets		
Property, plant and equipment	8,988.21	7,155.06
Right of use assets	740.26	-
Capital work-in-progress	1,851.10	740.04
Other intangible assets	45.53	21.28
Financial assets		
Investments	1.33	1.43
Other financial assets	547.03	788.84
Other non-current assets	4.93	9.03
Total non-current assets	12,178.39	8,715.68
Current assets		
Inventories	240.99	213.42
Financial assets		
Investments	1,142.68	168.66
Trade receivables	418.90	572.13
Cash and cash equivalents	3,683.19	230.11
Bank balances other than above	1,203.47	2,782.40
Other financial assets	3.79	5.50
Other current assets	177.48	125.43
Total current assets	6,870.50	4,097.65
TOTAL ASSETS	19,048.89	12,813.33
EQUITY AND LIABILITIES		
Equity		
Equity share capital	655.66	655.66
Other equity	12,906.76	11,034.72
Non-controlling interest	0.04	(2.99)
Total equity	13,562.46	11,687.39
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	3,217.45	-
Lease liabilities	623.41	-
Deferred tax liabilities [net]	71.17	37.45
Other non current liabilities	0.40	-
Provisions	49.69	30.95
Total non-current liabilities	3,962.12	68.40
Current liabilities		
Financial Liabilities		
Borrowings	39.68	-
Lease liabilities	50.91	-
Trade payables:		
Dues to micro and small enterprises	105.31	77.67
Dues to other than micro and small enterprises	923.82	544.73
Other current liabilities	248.43	226.92
Provisions	153.67	186.18
Current tax liabilities [net]	2.49	22.04
Total current liabilities	1,524.31	1,057.54
TOTAL EQUITY AND LIABILITIES	19,048.89	12,813.33

[Handwritten Signature]



[Handwritten Signature]



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: U85100MH2002PLC137908

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025


(₹ In Million)

Particulars	Unaudited	Unaudited	Unaudited	Audited	Audited
	quarter ended	quarter ended	quarter ended	year ended	year ended
	31st March	31st December	31st March	31st March	31st March
	2025	2024	2024	2025	2024
Revenue from Operations	3,267.41	3,220.19	2,913.77	12,615.45	10,734.36
Other income	70.28	69.20	80.63	286.75	220.46
TOTAL INCOME	3,337.69	3,289.39	2,994.40	12,902.20	10,954.82
EXPENSES					
Cost of materials consumed	-	-	-	-	-
Purchases of Stock-in-Trade	594.89	603.27	533.62	2,329.19	1,918.09
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	16.58	(15.30)	(5.80)	(27.56)	(23.41)
Employee benefits expense	538.03	555.39	514.64	2,144.99	1,899.36
Finance costs	55.71	27.83	9.25	105.54	263.41
Depreciation and amortisation expense	176.17	139.71	103.87	569.84	423.82
Professional Fees	812.19	788.94	717.16	3,121.23	2,713.58
Other expenses	523.17	524.00	522.49	2,081.96	1,805.82
TOTAL EXPENSES	2,716.74	2,623.84	2,395.23	10,325.19	9,000.67
Profit before exceptional items and tax	620.95	665.55	599.17	2,577.01	1,954.15
Exceptional items [net credit/ (charge)]	-	-	22.82	-	-
Profit before tax	620.95	665.55	621.99	2,577.01	1,954.15
Tax expenses	172.22	140.41	169.34	642.01	188.03
Current tax	140.00	136.82	159.27	604.34	518.87
Adjustments in respect of current income tax of previous year	-	-	3.27	-	1.52
Deferred tax credit/(charge)	32.22	3.59	6.80	37.67	(332.36)
PROFIT FOR THE PERIOD (A)	448.73	525.14	452.65	1,935.00	1,766.12
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified subsequently to profit or loss					
Remeasurements of the net defined benefit plans	(15.69)	-	(9.13)	(15.69)	(9.13)
Others	-	-	-	-	21.55
Income tax relating to items that will not be reclassified to profit or loss	3.94	-	-	3.94	-
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	(11.75)	-	(9.13)	(11.75)	12.42
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	436.98	525.14	443.52	1,923.25	1,778.54
Profit for the period attributable to:					
Owner of the Company	448.58	524.04	450.51	1,931.97	1,751.36
Non-controlling Interest	0.15	1.10	2.14	3.03	14.76
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	655.66	655.66	655.66
Other Equity	-	-	-	12,906.80	11,031.73
Earnings per equity share (Face value of Re. 10 each)					
Basic (in ₹)	6.84	7.99	6.49	29.47	28.44
Diluted (in ₹)	6.84	7.99	6.49	29.47	28.44
	(Not annualised)	(Not annualised)	(Not annualised)		

[Signature]



[Signature]




Jupiter Life Line Hospitals Limited
Audited Consolidated Statement of Cash Flow for the period ended March 31, 2025

₹ in Million

	For the year ended March 31, 2025	For the year ended March 31, 2024
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,577.01	1,954.15
Adjustments for:		
Share of Profit in partnership firms	(47.08)	(30.84)
Depreciation and amortisation expense	569.84	423.82
Loss/(gain) from sale of property plant and equipment	29.16	(0.03)
Finance Cost	75.89	263.41
Interest on lease liabilities	29.65	
Provision for employee benefit expenses	-	12.42
Bad debt written off	14.13	13.93
Expected Credit Loss on trade receivables	19.09	8.25
Dividend received	(0.08)	(0.14)
Interest Income	(197.55)	(193.87)
Net loss/(gain) arising on sale of investments	(44.64)	
Net loss/(gain) arising on fair valuation of investments	(18.57)	-
Operating profit before working capital changes	3,006.85	2,451.10
Adjustment for (increase)/decrease in operating assets		
Trade receivable	120.01	(137.45)
Inventories	(27.57)	(23.41)
Other financial and non current assets	41.83	(514.69)
Other current assets	0.21	(35.20)
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	73.70	(84.85)
Current, non current liabilities and provision	(7.56)	(13.46)
Cash Generated from operations	3,207.47	1,642.04
Income tax paid (net)	(674.43)	(496.83)
Net Cash from operating activities (A)	2,533.04	1,145.21
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant and equipment, CWIP and intangible assets	(3,207.26)	(852.95)
Proceeds from sale of Property, plant and equipment	4.03	1.23
Investments in Corporates and Partnership Firms	31.20	13.02
Investments in mutual fund	(3,444.83)	(227.49)
Proceed from mutual fund	2,550.00	99.11
Proceeds from /(Investments in) fixed deposit	1,782.99	(1,729.97)
Interest income	197.55	235.48
Dividend received	0.08	0.14
Net Cash flow from Investing Activities (B)	(2,086.24)	(2,461.43)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceed from issue of equity shares (net of share issue expenses)	-	6,326.27
Proceed / (Repayment) of Long Term Borrowings	3,217.45	(4,563.58)
Proceed / (Repayment) of Short Term Borrowings	39.68	(161.20)
Principal & interest Payment of Lease Liability	(109.39)	-
Dividend paid on equity share	(65.57)	(56.52)
Interest Paid	(75.89)	(263.41)
Net Cash flow from Financing Activities (C)	3,006.28	1,281.56
Net Increase in Cash and Cash equivalent (A + B + C)	3,453.08	(34.66)
Opening Balance of Cash and Cash equivalent	230.11	264.77
Closing Balance of Cash and Cash equivalent	3,683.19	230.11
Net Increase in Cash and Cash equivalent	3,453.08	(34.66)

[Handwritten Signature]



NOTES TO CONSOLIDATED FINANCIAL RESULTS:

1. These results have been prepared on the basis of the audited consolidated financial statements for the year ended March 31, 2025 and the audited consolidated condensed interim financial statements up to the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. These results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 09, 2025.
2. The statutory auditors have expressed an unmodified audit opinion on consolidated financial results for the year ended March 31, 2025 in terms of SEBI circular CIR/CFD/CMD/56/2016 dated May 27, 2016.
3. As per the Companies Act, 2013 a – “subsidiary company” or “subsidiary”, in relation to any other company (that is to say the holding company), means a company in which the holding company—
 - (i) controls the composition of the Board of Directors; or
 - (ii) exercises or controls more than one-half of the total share capital either at its own or together with one or more of its subsidiary companies.

The entities considered in the Limited Review financial statements are listed below:

Name of the company	Country of Incorporation	Proportion of ownership interest
Jupiter Hospital Projects Private Limited	India	96.56%
Medulla Healthcare Private Limited	India	100.00%
Jupiter Hospital Pharmacy Private Limited *	India	95.00%

(* Note: Jupiter Pharmacy got converted into Jupiter Hospital Pharmacy Private Limited on 2nd March, 2025)

In case of non-body corporate (partnership firms), consolidation is done on the net income basis [share of profit/(loss)], reflected in the head other income in consolidated statement of profit & loss.

The non-body corporates which are considered on net income basis are listed below:

Name of the entity	Country of Incorporation	Proportion of ownership interest
Jupiter Pharmacy	India	95%
Katyayini Hospitality	India	95%
Jupiter Gait Lab	India	51%

4. The Financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendments thereafter.
5. The Group operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements.



Ahalika

The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.

6. The Board of Directors of the holding company have recommended a final dividend of ₹ 1/- per equity share of ₹ 10/- each, for the year ended March 31, 2025.
7. Previous period figures have been regrouped/ reclassified to conform the current period classification wherever required.
8. The financial results are available on BSE and NSE websites along with company's website (www.jupiterhospital.com)

For Jupiter Life Line Hospitals Limited

A. Thakker

Dr Ankit A. Thakker
Whole Time Director and CEO
DIN: 02874715
Mumbai
May 09 ,2025



Independent Auditor's Report on Audit of Annual Standalone Financial Results and Review of Quarterly Financial Results

TO THE BOARD OF DIRECTORS OF

JUPITER LIFE LINE HOSPITALS LIMITED

Opinion & Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2025 (refer Other Matters section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2025 ("the Statement") of JUPITER LIFE LINE HOSPITALS LIMITED ("the Company"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us the Standalone Financial Results for the year ended March 31, 2025:

i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, 2015, as amended; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2025

With respect to the Standalone Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Standalone Financial Results

This statement which includes the Standalone Financial Results is the responsibility of the Company’s Board of Directors and has been approved by them for issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company’s financial reporting process.



Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the



scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2025

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware -of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


Other Matter

The statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listings Regulations. Our report on the Statement is not modified in respect of this matter.

For ASWIN P. MALDE & CO.

Chartered Accountants

Firm's Registration No. 100725W




ASWIN P. MALDE

(Proprietor)

Membership No. 032662


UDIN: 25032662BMJBTS7482



Date: May 09, 2025



Jupiter Life Line Hospitals Limited
Audited Standalone Balance Sheet as at March 31, 2025

Particulars	₹ In Million	
	As at March 31, 2025	As at March 31, 2024
ASSETS		
Non-current assets		
Property, plant and equipment	6,348.42	4,765.28
Right of use assets	740.26	-
Capital work-in-progress	1,625.62	611.04
Other intangible assets	43.32	7.91
Financial assets		
Investments	940.34	940.34
Other financial assets	540.53	736.29
Other non-current assets	206.16	2,707.92
Total non-current assets	10,444.65	9,768.78
Current assets		
Inventories	181.74	167.65
Financial assets		
Investments	1,142.68	168.66
Trade receivables	365.56	463.54
Cash and cash equivalents	3,674.10	189.80
Bank balances other than above	1,203.47	2,782.15
Other financial assets	3.79	5.50
Other current assets	87.43	59.87
Total current assets	6,658.77	3,837.17
TOTAL ASSETS	17,103.42	13,605.95
EQUITY AND LIABILITIES		
Equity		
Equity share capital	655.66	655.66
Other equity	13,569.76	11,796.89
Total equity	14,225.42	12,452.55
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	742.50	-
Lease liabilities	623.41	-
Deferred tax liabilities [net]	257.51	248.30
Other non current liabilities	-	-
Provisions	38.85	22.08
Total non-current liabilities	1,662.27	270.38
Current liabilities		
Financial Liabilities		
Borrowings	7.50	-
Lease liabilities	50.91	-
Trade payables:		
Dues to micro and small enterprises	101.12	60.70
Dues to other than micro and small enterprises	720.44	444.71
Other financial liabilities		
Other current liabilities	209.60	190.54
Provisions	123.67	165.03
Current tax liabilities [net]	2.49	22.04
Total current liabilities	1,215.73	883.02
TOTAL EQUITY AND LIABILITIES	17,103.42	13,605.95





STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(₹ In Million)

Particulars	Unaudited	Unaudited	Unaudited	Audited	Audited
	quarter ended	quarter ended	quarter ended	year ended	year ended
	31st March	31st December	31st March	31st March	31st March
	2025	2024	2024	2025	2024
Revenue from Operations	2,739.13	2,704.96	2,461.16	10,599.98	9,145.69
Other income	69.52	67.65	79.38	281.38	256.92
TOTAL INCOME	2,808.65	2,772.61	2,540.54	10,881.36	9,402.61
EXPENSES					
Purchases of Stock-in-Trade	494.90	499.03	447.94	1,925.91	1,599.96
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	15.41	(11.56)	2.19	(14.08)	(12.71)
Employee benefits expense	441.37	459.23	425.32	1,772.23	1,586.09
Finance costs	40.02	26.54	9.25	86.05	186.55
Depreciation and amortisation expense	133.77	106.36	74.69	424.08	305.23
Professional Fees	647.00	640.80	583.93	2,523.95	2,209.65
Other expenses	418.37	429.41	429.90	1,699.78	1,489.63
TOTAL EXPENSES	2,190.84	2,149.81	1,973.22	8,417.92	7,364.40
Profit before exceptional items and tax	617.81	622.80	567.32	2,463.44	2,038.21
Exceptional items [net credit/ (charge)]	-	-	22.82	-	-
Profit before tax	617.81	622.80	590.14	2,463.44	2,038.21
Tax expenses	173.34	129.73	158.67	616.42	518.68
Current tax	139.99	136.82	159.27	604.33	518.87
Adjustments in respect of current income tax of previous year	-	-	3.27	-	1.52
Deferred tax credit/(charge)	33.35	(7.09)	(3.87)	12.09	(1.71)
PROFIT FOR THE PERIOD (A)	444.47	493.07	431.47	1,847.02	1,519.53
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified subsequently to profit or loss					
Remeasurements of the net defined benefit plans	(11.46)	-	(8.52)	(11.46)	(8.52)
Others	-	-	-	-	21.55
Income tax relating to items that will not be reclassified to profit or loss	2.88	-	-	2.88	-
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	(8.58)	-	(8.52)	(8.58)	13.03
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	435.89	493.07	422.95	1,838.44	1,532.56
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	655.66	655.66	655.66
Other Equity	-	-	-	13,569.76	11,796.89
Earnings per equity share (Face value of Re. 10 each)					
Basic (in ₹)	6.78	7.52	6.47	28.17	24.68
Diluted (in ₹)	6.78	7.52	6.47	28.17	24.68
	(Not annualised)	(Not annualised)	(Not annualised)		

[Handwritten Signature]



[Handwritten Signature]




Jupiter Life Line Hospitals Limited
Audited Standalone Statement of Cash Flow for the year ended March 31, 2025

₹ In Million

	For the year ended March 31, 2025	For the year ended March 31, 2024
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,463.44	2,038.21
Adjustments for:		
Share of Profit in partnership firms	(47.16)	(31.70)
Depreciation and amortisation expense	424.08	305.23
Loss/(gain) from sale of property plant and equipment	25.77	(0.03)
Finance Cost	56.40	186.55
Interest on lease liabilities	29.65	-
Bad debt written off	-	13.93
Expected Credit Loss on trade receivables	10.17	8.25
Dividend received	(0.08)	(0.14)
Interest Income	(195.83)	(232.35)
Net loss/(gain) arising on sale of investments	(44.64)	-
Net loss/(gain) arising on fair valuation of investments	(18.57)	-
Operating profit before working capital changes	2,703.23	2,287.95
Adjustment for (increase)/decrease in operating assets		
Trade receivable	87.81	(85.47)
Inventories	(14.09)	(12.71)
Other financial and non current assets	38.17	(514.69)
Other current assets	(25.85)	0.78
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	50.38	(118.97)
Current, non current liabilities and provision	(16.99)	37.85
Cash Generated from operations	2,822.66	1,594.74
Income tax paid (net)	(623.88)	(496.83)
Net Cash from operating activities (A)	2,198.78	1,097.91
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant and equipment, CWIP and intangible assets	(2,804.12)	(763.56)
Proceeds from sale of Property, plant and equipment	0.71	1.23
Investments in Corporates and Partnership Firms	31.18	5.50
Investments in mutual fund	(3,444.83)	(227.49)
Proceed from mutual fund	2,550.00	99.11
Proceeds from /(Investments in) fixed deposit	1,738.29	(1,727.65)
Interest income	195.83	232.35
Dividend received	0.08	0.14
Net Cash flow from Investing Activities (B)	(1,732.86)	(2,380.37)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceed from issue of equity shares (net of share issue expenses)	-	6,326.27
Loans/advances to subsidiary	2,499.74	(1,886.96)
Proceed / (Repayment) of Long Term Borrowings	750.00	(2,946.88)
Proceed / (Repayment) of Short Term Borrowings	-	(30.54)
Principal & interest Payment of Lease Liability	(109.39)	-
Dividend paid on equity share	(65.57)	(56.52)
Interest Paid	(56.40)	(186.55)
Net Cash flow from Financing Activities (C)	3,018.38	1,218.82
Net Increase in Cash and Cash equivalent (A + B + C)	3,484.30	(63.64)
Opening Balance of Cash and Cash equivalent	189.80	253.44
Closing Balance of Cash and Cash equivalent	3,674.10	189.80
Net Increase in Cash and Cash equivalent	3,484.30	(63.64)

[Handwritten Signature]



[Handwritten Signature]



NOTES TO STANDALONE FINANCIAL RESULTS:

1. These results have been prepared on the basis of the audited standalone financial statements for the year ended March 31, 2025 and the audited standalone condensed interim financial statements up to the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. These results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 09, 2025.
2. The statutory auditors have expressed an unmodified audit opinion on standalone financial results for the year ended March 31, 2025 in terms of SEBI circular CIR/CFD/CMD/56/2016 dated May 27, 2016.
3. The Financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendments thereafter.
4. The Company operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements. The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
5. The Board of Directors have recommended a final dividend of ₹ 1 per share for the year ended March 31, 2025.
6. Previous period figures have been regrouped/reclassified to conform the current period classification wherever required.
7. The financial results are available on BSE and NSE websites along with company's website (www.jupiterhospital.com)

For Jupiter Life Line Hospitals Limited

AA Thakker

Dr Ankit A. Thakker
Whole Time Director and CEO
DIN: 02874715
Mumbai
May 9, 2025



Annexure II

May 09, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/ Madam,

In compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we hereby declare that, Statutory Auditors of our Company M/s. Aswin P. Malde, Chartered Accountants (FRN: 100725W) have issued an Audit Report with unmodified opinion on Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you.

For JUPITER LIFE LINE HOSPITALS LIMITED

Mr. Harshad Purani
President Admin And Head - CSR & CFO

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Dr. Ankit Thakker as Joint Managing Director and continuing as CEO of the Company.
2.	Date of appointment	Appointment of Dr. Ankit Thakker (DIN: 02874715) as a Joint Managing Director of the Company for a period of five years with effect from July 11, 2025, subject to approval of the members at the ensuing Annual General Meeting of the Company.
3.	Term of appointment	Appointment of Dr. Ankit Thakker (DIN: 02874715) as a Joint Managing Director for a period of five years, w.e.f. July 11, 2025, till July 10, 2030, subject to approval of the members at the ensuing Annual General Meeting of the Company
4.	Brief Profile	<p>Dr. Ankit Thakker has been serving the Company as an Executive Director and Chief Executive Officer and he is also responsible for the overall management of the Company.</p> <p>He is a medical doctor with a master's in management from the London School of Economics and Political Science.</p> <p>Dr. Ankit Thakker has been associated with Company since 2014.</p>
5.	Disclosure of relationships between Directors	Dr. Ankit Thakker is Son of Dr. Ajay Thakker
6.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Dr. Ankit Thakker is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Description
1.	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc	<p><u>Transferor Company:</u> Medulla Healthcare Private Limited was incorporated as a private limited company under the Companies Act, 2013 on the 29th June 2022 in the state of Maharashtra. The CIN of the Transferor Company as on date is U85300MH2022PTC385705. The Transferor Company is a wholly-owned subsidiary of the Transferee Company.</p> <p><u>Transferee Company:</u> Jupiter Life Line Hospitals Limited was originally incorporated as a public limited company under the erstwhile Companies Act, 1956, on the 18th November 2002 in the State of Maharashtra. The CIN of the Transferee Company as on date is L85100MH2002PLC137908. JLHL is a listed company having its equity shares listed on BSE Limited and National Stock Exchange of India Limited.</p> <p>The financial details of the Companies are provided in 'Exhibit 1'.</p>
2.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length";	<p>Yes. The Transferor Company is a direct wholly-owned subsidiary of the Transferee Company and as such the said companies are related party to each other.</p> <p>However, the Ministry of Corporate Affairs has clarified vide its General Circular No. 30/ 2014 dated 17th July 2014 that transactions arising out of Compromise, Arrangements and Amalgamations dealt with under specific provisions of the Companies Act, 2013, will not fall within the purview of related party transaction in terms of Section 188 of the Companies Act, 2013.</p> <p>Further, pursuant to Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the related party transaction provisions are not applicable to the proposed Scheme and the Scheme is also exempted from the provisions of SEBI Master Circular No.</p>

		SEBI/HO/CFD/POD2/P/CIR/2023/93 dated 20 th June 2023. The Transferor Company, being wholly owned subsidiaries of the Company, are proposed to be amalgamated with the Company through Scheme of Arrangement, requirement of arm's length criteria is not applicable.
3.	Area of business of the entity(ies);	<p><u>Transferor Company:</u> Medulla was incorporated with the main objects to run, undertake, execute, manage, develop, own, acquire, establish the business in India or elsewhere to carry out all kinds of activities in healthcare, pharmaceutical, laboratories, diagnostic centres and rehabilitation centers, hospitality, etc.</p> <p><u>Transferee Company:</u> JLHL is a prominent multi-speciality tertiary and quaternary healthcare service provider in the Mumbai metropolitan area and western India with total operational bed capacity of 961 across three hospitals located in Thane, Pune and Indore under the “Jupiter” Brand. The Company is constructing a new Multi - speciality hospital in Dombivali, Maharashtra with potential capacity of 500 beds and It has also taken a land on lease for setting up its second hospital in Pune with potential capacity of 500 beds. JLHL is also running Fortune Park Lake City Hotel in Thane for promoting medical tourism. JLHL has also purchased a land for setting up its hospital at Ghodbunder Mira Road, District Thane, its 6th Hospital project boasting a capacity of 300 beds.</p>
4.	Rationale for amalgamation/merger;	<p><u>Rationale of the scheme</u> The Transferor Company is a direct wholly-owned subsidiary of the Transferee Company. The Scheme is proposed as a part of consolidation strategy within the Group. The objects / rationale of the proposed Scheme are as under:</p> <ul style="list-style-type: none"> • The merger of Transferor Company into Transferee Company will result in cost optimization; • The Scheme will also achieve rationalization of costs by simplification of management structure leading to better administration and cost savings; • Rationalization of the group holding structure by way of reduction in the number of entities and streamline the structure of Transferee Company; • Providing an opportunity to leverage combined assets, capabilities, experience, expertise, infrastructure of both companies enabling optimum utilization of existing resources and economies of scale;

		<ul style="list-style-type: none"> Significant reduction in the multiplicity of legal and regulatory compliances required at present to be carried out by Transferor Company, and greater financial strength and flexibility for the Transferee Company, which would result in maximizing overall shareholder value.
5.	In case of cash consideration - amount or otherwise share exchange ratio;	The entire issued, subscribed and paid-up share capital of the Transferor Company is held by the Transferee Company along with its nominees. Hence, the Transferor Company is directly and beneficially owned by the Transferee Company along with its nominees. Accordingly, the Transferor Company is a direct wholly-owned subsidiary of the Transferee Company. Thus, upon the Scheme becoming effective, neither any consideration will be paid nor any shares shall be issued by the Transferee Company to the shareholders of the Transferor Company and consequent upon the merger, the shares of the Transferor Company held by the Transferee Company directly, shall stand cancelled.
6.	Brief details of change in shareholding pattern (if any) of listed entity.	There will be no change in the shareholding pattern of the Company pursuant to the Scheme, as no shares are being issued by the Company in connection with the Scheme.

Exhibit – I

Financial details as on 31st March 2025

(Rs. in million)

<u>Particulars</u>	<u>Transferor Company</u>	<u>Transferee Company</u>
Paid-up Equity Share Capital	Rs.0.10	Rs. 655.66
Net Worth – Equity Share Capital + Other Equity (Standalone)	Rs. 0.14	Rs.14225.42
Total Income (Revenue from Operations + Other Income) (Standalone)	Rs. 0.01	Rs.10881.36

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Name	Mr. Sivasis Sen
2.	Reason for change viz. — appointment, — re appointment, resignation, removal, death or otherwise;	Appointment of CFO
3.	Date of appointment/ cessation / Change (as applicable) & Term of Appointment	May 12, 2025, effective from the opening of the business hours. Mr. Sivasis Sen Appointed as Chief Financial Officer and Key Managerial Personnel of the Company by the Board of Directors.
4.	Brief Profile (in case of appointment);	Mr. Sivasis is seasoned Chartered Accountant with over 25 years of diverse experience spanning finance leadership, strategic planning, risk management, and corporate governance across multiple industries and geographies. Proven track record in managing complex supply chains, financial operations, and ERP implementations in listed and family-owned entities. He has held several senior finance roles across South Asia and the Asia-Pacific region, including CFO of Vesuvius India, and Mars India. Prior to that he has also served in various roles in Johnson & Johnson and Taj Hotels. He is skilled in stakeholder management, regulatory compliance, internal controls, and driving business transformation. Adept at leading large, cross-functional and remote teams, with strong expertise in budgeting, forecasting, and capital planning. He is known for establishing shared service environments and embedding financial best practices across organizations.
5.	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not Applicable

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. — appointment, — re-appointment, — resignation, removal, death or otherwise;	Mr. Harshad Purani demand on the time and attention for the leadership activities are increasing as the company continues on its growth path the scope and scale are increasing. In order to focus on his role as President Administration and Head CSR, Mr. Harshad Purani will continue to hold the positions of President Administration and Head CSR (SMP).
2.	Date of appointment/ cessation / Change (as applicable) & term of appointment;	Effective from opening hours of May 12, 2025
3.	Detail Reason for Change	Kindly refer Letter as attached.
4.	Brief Profile (in case of appointment);	Not Applicable
5.	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not Applicable

Date: 1st May, 2025

To,
The Board of Directors
Jupiter Life Line Hospitals Limited
Jupiter Hospital Eastern Express Highway,
Thane west 400601

Subject: Focusing on Administrative responsibilities and CSR.

Dear Members of the Board,

As the company continues on its growth path the scope and scale of our operations is increasing. My demand on my time and attention for the leadership activities is increasing. In order to focus on. My role as Head – CSR and President (Administration), I am requesting you to relieve me from my responsibilities as Chief Financial Officer (CFO) of Jupiter Life Line Hospitals Limited, w.e.f. 12th May, 2025.

After careful consideration and in consultation with the management, we have identified my potential successor and I request the board to accept the new nomination and allow me to cease from the CFO role to focus on my continuing responsibilities as President – Administration and Head – CSR of the Company. I remain fully committed to the Company's vision and operations and look forward to contributing meaningfully in these capacities.

Please consider this letter as my formal intimation in accordance with applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I would like to express my sincere gratitude to the Board for their understanding and look forward to scaling new heights for the company together.

Warm regards,



Mr. Harshad Purani
Chief Financial Officer
President – Admin & Head – CSR

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. KKC & Associates LLP as Statutory Auditor of the company.
2.	Date of appointment	From the conclusion of the 23 rd AGM till the conclusion of the 28 th AGM
3.	Term of appointment	Term of Five Years
4.	Brief Profile	M/s. KKC & Associates, LLP, Chartered Accountants (Formerly known as Khimji Kunverji & Co., LLP) established in the year 1936. It has presence in 4 cities in the country with the team size of 350+. The core team has experience in Banking & Financial Services, Manufacturing & Services, Taxation (Direct & Indirect) and Information Technology. The firm has 15 partners consisting of distinguished Chartered Accountants. The Firm has been in existence for 86+ years with dedicated, focused, specialized and well-structured team.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. Yogesh Sharma & Co as Secretarial Auditor of the Company.
2.	Date of appointment	May 09, 2025
3.	Term of appointment	Appointed for a period of five consecutive years, commencing from FY 2025-2026 to FY 2029-2030, subject to approval of the members at the ensuing Annual General Meeting of the Company
4.	Brief Profile	<p>Mr. Yogesh M. Sharma is a Fellow Member of Institute of Company Secretaries of India since more than 15 years. He also holds a Degree in Law. He is also Post Graduate in Commerce and also holds Master's Degree in Finance and Marketing.</p> <p>He has been in Practice since last 15 years providing Legal and Corporate Consultancy to various Listed and Unlisted Companies. He has also appeared in NCLT in various matters relating to Mergers and Amalgamations. His areas of Key expertise are Secretarial Audit and Annual Compliance Report under LODR as per SEBI Regulations.</p>

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. V. J. Talati & Co as Cost Auditor of the company.
2.	Date of appointment	May 09, 2025
3.	Term of appointment	Financial Year 2025- 26
4.	Brief Profile	M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Reappointment of M/s. Varma & Varma as Internal Auditor of the company.
2.	Date of appointment / re-appointment / /Cessation (as applicable)	May 09, 2025
3.	Term of appointment	Financial Year 2025- 26
4.	Brief Profile	<p>M/s. Varma & Varma is a Chartered Accountant Firm registered with Institute of Chartered Accountants of India with ICAI. The firm was established in 1935 and is led by 33 partners. The audit firm has valid peer review certificate.</p> <p>The firm had empanelled with the Comptroller and Auditor General of India (CAG), the Reserve Bank of India (RBI), World Bank, Securities and Exchange Board of India (SEBI), Audit Bureau of Circulations (ABC) etc.</p> <p>The firm provides a range of services which include audit & assurance, tax representation & advisory services, incorporation & investment advisory services, Business consultancy and valuation services. The firm has significant experience in providing auditing, taxation & advisory services to Hospitals and Healthcare clients.</p>

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Name of the SMP	Dr. Shilpa Tatake
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Change in Designation: Chief Operating Officer to Chief Executive Officer Thane Senior Management Personnel (SMP) of the Company.
3.	Date of appointment (Change in Designation)	Not Applicable, however the date of the change of designation is effective from May 09, 2025.
4.	Brief Profile (in case of Appointment)	Not Applicable
5.	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not Applicable

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

Sr. No.	Particulars	Remark
1.	Name of the SMP	Mr. Pradip Acharya
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Change in Designation: Head Corporate Relations to Group Head Industrial Health. In view of the aforementioned he ceases to act as a Senior Management Personnel (SMP) of the Company.
3.	Date of appointment (Change in Designation)	Not Applicable, however the date of the change of designation is effective from May 09, 2025.
4.	Brief Profile (in case of Appointment)	Not Applicable
5.	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not Applicable

Annexure XIII

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular

The following new other objects to be appended under Clause III (C) after the existing clauses 127 of the Memorandum of Association of Company:

128. To enter into Power Purchase Agreements (PPA), Wheeling Agreements (WA), Captive Power Purchase Agreements (CPPA), group captive arrangements, energy sale agreements and related contracts with government entities, private parties, distribution companies, transmission companies, or captive users, in accordance with the provisions of the Electricity Act, 2003, Electricity Rules, 2005, and procedures issued by the Central Electricity Authority (CEA) and other applicable authorities; and to undertake registration, compliance, verification, and reporting obligations with the Central Electricity Authority (CEA), State Load Dispatch Centers (SLDCs), Regional Load Dispatch Centers (RLDCs), distribution licensees, and any other statutory or regulatory authority in relation to captive generation or power sale projects.
129. To establish, operate, maintain, lease, purchase, or otherwise acquire transmission lines, substations, metering facilities, energy storage systems, and associated infrastructure necessary for generation, evacuation, distribution, transmission, storage, Battery Energy Storage System and supply of power, including for captive consumption or third-party sale; and to acquire, lease, sub-lease, license or otherwise deal in land, buildings, energy parks, solar parks, wind farms, and other immovable properties required for the establishment, operation and maintenance of solar, wind, hybrid, biomass, hydel, or any other renewable or non-renewable energy projects.
130. To engage in research, development, consultancy, advisory, technical training, and promotional activities in the field of renewable and non-renewable energy systems, energy conservation, energy efficiency enhancement, and sustainable energy solutions; to procure, manufacture, assemble, import, export, market, distribute, trade, install, commission, operate, or maintain machinery, materials, equipment, and apparatus required for energy generation, transmission, storage, and supply; to enter into contracts, collaborations, alliances, joint ventures, partnerships with Indian or foreign entities; and to do all such lawful acts, deeds, matters, and things as are necessary, ancillary, or conducive to the attainment of the foregoing objects, and to ensure compliance with laws, regulations, guidelines, and orders issued by the Central Government, State Governments, the Central Electricity Authority, Electricity Regulatory Commissions, and other competent authorities.